Please assess the completion status of the following clinical trial:

Trial Title: Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Male or female aged 18 to 60 years, inclusive at the time of Screening.~2. Diagnosed with ADHD using the DSM-5 criteria based on the Adults ADHD Clinical Diagnostic Scale (ACDS).~3. IQ within normal range based upon clinical opinion of the Investigator.~4. Baseline AISRS total score greater than or equal to 26.~5. Baseline score of 4 or higher in CGI-S.~6. Females who participate in this study will be of childbearing or non-childbearing potential:~   * Childbearing potential: Physically capable of becoming pregnant~  * Non-childbearing potential:~     * Permanently sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation for at least 6 weeks or documented successful hysteroscopic sterilization); and/or~    * Post-menopausal (no menstrual period for at least 12 consecutive months without any other medical cause).~7. Females of childbearing potential must be non-lactating and must have a negative serum pregnancy test at Screening.~8. Willing to use acceptable, effective methods of contraception.~9. Be able to attend the clinic regularly and reliably.~10. Be able to understand, read, write, and speak English fluently to complete the study related materials.~11. Be informed of the nature of the study and give written consent prior to any study procedure.~Exclusion Criteria:~1. Current or lifetime history of bipolar disorder or any psychotic disorder as established by Mini International Neuropsychiatric Interview (M.I.N.I.) 7.0.2.~2. Current history of major depression, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, or post-traumatic stress disorder as established by the M.I.N.I. 7.0.2.~3. Known history of chronic medical illnesses including untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, and known family history of sudden death.~4. History of uncontrolled hypertension or a resting systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg. Subjects with well-controlled hypertension on a stable dose for at least 3 months of anti-hypertensives will be allowed to participate.~5. Have clinically significant findings in vital signs measurements at Screening including:~   * Systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg~  * Heart rate \>100 bpm~6. Known history or presence of significant renal or hepatic disease, as indicated by clinical laboratory assessment:~   * Liver function test results ≥2 times the upper normal limit~  * Abnormal blood urea nitrogen, or creatinine levels~7. Clinically significant abnormal electrocardiogram or cardiac findings on physical examination (including the presence of a pathologic murmur).~8. Use of the following medications within 14 days of Baseline Visit:~   * Atomoxetine~  * Monoamine oxidase inhibitors (e.g., selegiline, isocarboxazid, phenelzine, tranylcypromine)~  * Tricyclic antidepressants (e.g., desipramine, protriptyline).~9. Use of the following medications within 3 days of Baseline Visit:~   * Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid hydrochloride \[HCl\], ascorbic acid)~  * Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts).~10. Use of fluoxetine within 30 days of Baseline Visit.~11. Use of stimulant medications within 1 week of Baseline Visit.~12. Planned use of prohibited drugs or agents from the Screening visit through the end of the study.~13. Participation in a clinical study in which an investigational drug was administered within 30 days prior to Screening.~14. Abnormal clinically significant laboratory test values at Screening that, in the opinion of the Medical Monitor or Sponsor, would preclude study participation.~15. Known history of allergy/hypersensitivity to amphetamine or any of the components of AMPH ER TAB.~16. Known history of lack of clinical response to amphetamine based upon Investigator judgment.~17. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.~18. Any uncontrolled medical condition that, in the opinion of Medical Monitor or Sponsor, would preclude study participation.~19. History or presence of alcohol dependence or substance abuse disorder according to DSM-5 or within the last 12 months.~20. Subject's inability or unwillingness to follow directions from the study research staff.~21. Answer of yes to questions 4 or 5 of the C-SSRS within the last 2 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- AMPH ER Tab (Type: ACTIVE_COMPARATOR): Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg
- Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Tablets 5, 10, 15 and 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).